Literature DB >> 12609692

Hallucinogen persisting perception disorder: what do we know after 50 years?

John H Halpern1, Harrison G Pope.   

Abstract

'Flashbacks' following use of hallucinogenic drugs have been reported for decades; they are recognized in DSM-IV as 'Hallucinogen Persisting Perception Disorder (Flashbacks)', or HPPD. We located and analyzed 20 quantitative studies between 1955 and 2001 examining this phenomenon. However, many of these studies were performed before operational criteria for HPPD were published in DSM-III-R, so they are difficult to interpret in the light of current diagnostic criteria. Overall, current knowledge of HPPD remains very limited. In particular (1) the term 'flashbacks' is defined in so many ways that it is essentially valueless; (2) most studies provide too little information to judge how many cases could meet DSM-IV criteria for HPPD; and consequently (3) information about risk factors for HPPD, possible etiologic mechanisms, and potential treatment modalities must be interpreted with great caution. At present, HPPD appears to be a genuine but uncommon disorder, sometimes persisting for months or years after hallucinogen use and causing substantial morbidity. It is reported most commonly after illicit LSD use, but less commonly with LSD administered in research or treatment settings, or with use of other types of hallucinogens. There are case reports, but no randomized controlled trials, of successful treatment with neuroleptics, anticonvulsants, benzodiazepines, and clonidine. Although it may be difficult to collect large samples of HPPD cases, further studies are critically needed to augment the meager data presently available regarding the prevalence, etiology, and treatment of HPPD. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609692     DOI: 10.1016/s0376-8716(02)00306-x

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

Review 1.  Hallucinogens: an update.

Authors:  John H Halpern
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 2.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

Review 3.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 4.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

5.  Hallucinogen persisting perception disorder in neuronal networks with adaptation.

Authors:  Zachary P Kilpatrick; G Bard Ermentrout
Journal:  J Comput Neurosci       Date:  2011-06-14       Impact factor: 1.621

6.  Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Authors:  Marc G Blainey
Journal:  J Relig Health       Date:  2015-02

Review 7.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

8.  New Onset LSD Flashback Syndrome Triggered by the Initiation of SSRIs.

Authors:  Sarah Goldman; David Galarneau; Richard Friedman
Journal:  Ochsner J       Date:  2007

9.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

10.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.